clofibric acid has been researched along with Hyperlipemia in 111 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We observed a case of chronic radiodermatitis which developed after cardiac catheterization, in a patient treated with corticosteroids and ciprofibrate for lupus." | 7.70 | [Chronic radiodermatitis after heart catheterization: the contributing role of ciprofibrate (Lipanor)?]. ( Gironet, N; Jan, V; Lorette, G; Machet, L; Machet, MC; Vaillant, L, 1998) |
| "The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III)." | 7.66 | [Bezafibrate in primary hyperlipidemias (author's transl)]. ( Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1982) |
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | 6.70 | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| "In a randomised blind study with 404 patients 1 capsule Etofibrate per day (500 mg) in sustained release dosage form was tested in comparison to other lipid-lowering drugs." | 6.65 | [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations]. ( Füsgen, I; Summa, JD, 1980) |
| "The aim of this study was to study the effect of adding polyunsaturated fatty acid (PUFA) n-3 or placebo (containing oleic acid) to a combined statin-fibrate treatment on plasma lipoproteins, lipoperoxidation, glucose homeostasis, total homocysteine (tHcy) and microalbuminuria (MA) in patients with diabetic dyslipidemia (DDL)." | 5.12 | N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination. ( Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M, 2006) |
| " We evaluated the effect of etofibrate on the LDL-subtype distribution in patients with type 2 diabetes mellitus (n = 13, 55 +/- 18 years, BMI 27." | 5.10 | Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. ( Dietlein, M; Geiss, HC; Parhofer, KG, 2003) |
| " In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe." | 4.84 | [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. ( Balcerak, M; Broncel, M; Chojnowska-Jezierska, J, 2007) |
| " Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited." | 4.82 | Management of dyslipidemia in patients with complicated metabolic syndrome. ( Davidson, MH, 2005) |
| "Oxidative stress and inflammation have been considered the main factors in the liver injury of clofibrate (CF)." | 4.02 | The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity. ( Cheng, L; Guo, M; He, Y; Jiang, H; Liu, J; Ren, C; Shi, Y; Sun, M; Wang, B; Wang, W; Wang, X; Xie, Y; Xu, X, 2021) |
| "We observed a case of chronic radiodermatitis which developed after cardiac catheterization, in a patient treated with corticosteroids and ciprofibrate for lupus." | 3.70 | [Chronic radiodermatitis after heart catheterization: the contributing role of ciprofibrate (Lipanor)?]. ( Gironet, N; Jan, V; Lorette, G; Machet, L; Machet, MC; Vaillant, L, 1998) |
| "The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III)." | 3.66 | [Bezafibrate in primary hyperlipidemias (author's transl)]. ( Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1982) |
| "Hyperlipidemia is found to be associated with changes in fatty acid (FA) profiles." | 2.74 | Serum and erythrocyte membrane phospholipids fatty acid composition in hyperlipidemia: effects of dietary intervention and combined diet and fibrate therapy. ( Glibetic, M; Ristic-Medic, D; Suzic, S; Takic, M; Tepsic, J; Vucic, V, 2009) |
| "Sixty-three patients with type IIa dyslipidemia were randomized to fluvastatin (40 mg daily; n = 33) or simvastatin (20mg daily; n = 30), while 68 type IIb dyslipidemic patients were treated with micronized ciprofibrate (100mg daily; n = 34) or micronized fenofibrate (200mg daily; n = 34)." | 2.71 | The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. ( Belowski, D; Herman, ZS; Kowalski, J; Krysiak, R; Labuzek, K; Madej, A; Okopień, B; Zieliński, M, 2004) |
| "Etofibrate is a hybrid drug which combines niacin with clofibrate." | 2.70 | Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. ( Coelho, OR; Mansur, AP; Maranhão, RC; Ramires, JA; Rodrigues-Sobrinho, CR; Sposito, AC, 2001) |
| "Mixed hyperlipidemia is a common risk factor for cardiovascular disease." | 2.70 | Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. ( Aguilar-Salinas, CA; Fanghänel-Salmón, G; Gómez Pérez, FJ; González-Valdez, H; Gulías-Herrero, A; Meza, E; Monterrubio-Flores, EA; Montes, J; Sánchez, L, 2001) |
| "Ciprofibrate did not inhibit thromboxane B 2 synthesis in platelets." | 2.70 | Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects. ( Cibulová, L; Dzúrik, R; Gajdos, M; Huttová, D; Krivosíková, Z; Mongiellová, V; Spustová, V, 2001) |
| "Etofibrate is a hypolipemic drug belonging to the fibrate class." | 2.69 | Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome. ( Chelstowski, K; Jastrzebska, M; Kopciewicz, J; Naruszewicz, M; Pieczul-Mróz, J; Torbus-Lisiecka, B, 1999) |
| "Out of 12 patients with primary hyperlipidemia (HL) included in the study ischemic heart disease was diagnosed in 4 and hypertension stage I-II in 6 patients." | 2.68 | [A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia]. ( Kotova, LA; Kukharchuk, VV; Rozhkova, TA; Semenova, OA; Tvorogova, MG, 1996) |
| " Adverse effects were observed in 8." | 2.68 | [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study]. ( dos Santos, JE; Loures-Vale, AA; Martinez, TL; Novazzi, JP; Rabelo, LM, 1996) |
| " Adequate dosage in RDT patients was found to be 200mg every 3rd day." | 2.65 | Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients. ( Grützmacher, P; Lang, W; Scheuermann, E, 1981) |
| "In a randomised blind study with 404 patients 1 capsule Etofibrate per day (500 mg) in sustained release dosage form was tested in comparison to other lipid-lowering drugs." | 2.65 | [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations]. ( Füsgen, I; Summa, JD, 1980) |
| "These patients often have dyslipidemia, including low levels of HDL cholesterol and elevated levels of triglycerides and small, dense LDL." | 2.45 | Myopathy with statin-fibrate combination therapy: clinical considerations. ( Jacobson, TA, 2009) |
| "Since abnormal postprandial lipemia is associated with pathologic conditions, its treatment is of clinical importance." | 2.44 | Therapeutic effects of fibrates in postprandial lipemia. ( Anagnostopoulou, KK; Cokkinos, DV; Kolovou, GD; Kostakou, PM, 2008) |
| "Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL." | 2.44 | Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008) |
| "Treatment of HIV dyslipidemia should include lifestyle modifications such as a low-fat diet, increased exercise, reduced alcohol consumption and smoking cessation." | 2.43 | Strategies for management and treatment of dyslipidemia in HIV/AIDS. ( Sax, PE, 2006) |
| "The approach to the management of hyperlipidemia has evolved dramatically over the past decade." | 2.43 | Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. ( Balbisi, EA, 2006) |
| "Although type 2 diabetes is associated with a clustering of risk factors, the cause for an excess risk of cardiovascular disease remains unknown." | 2.41 | Lipids in type 2 diabetes. ( Laakso, M, 2002) |
| "Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance." | 2.39 | Drug interactions with fibric acids. ( Dujovne, CA; Lozada, A, 1994) |
| "Ciprofibrate is a compound newly introduced into the United Kingdom which shares many pharmacokinetic properties with other fibrates." | 2.38 | Ciprofibrate--a profile. ( Betteridge, DJ, 1993) |
| "In this observational study, the long-term use of statins or fibrates was not associated with a substantially altered relative risk of developing PD." | 1.35 | Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. ( Becker, C; Jick, SS; Meier, CR, 2008) |
| "Myositis was significantly associated with statin monotherapy (RR 2." | 1.34 | Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. ( Glanz, M; Hokanson, JE; McClure, DL; Murphy, JR; Valuck, RJ, 2007) |
| "Overall 32." | 1.33 | APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. ( Alpérovitch, A; Amouyel, P; Dartigues, JF; Dufouil, C; Fiévet, N; Richard, F; Ritchie, K; Tzourio, C, 2005) |
| "Fenofibrate treatment decreased hepatic macrophage accumulation and abolished steatosis." | 1.33 | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. ( Buffat, L; Gijbels, MJ; Hofker, MH; Maeda, N; Noel, B; Shiri-Sverdlov, R; Staels, B; van Bilsen, M; van Gorp, PJ; Wouters, K, 2006) |
| "The ciprofibrate was suspended after the 8th week for a 4 weeks period and the triglyceride and the fibrinogen levels increased whereas the HDL cholesterol level decreased significantly." | 1.31 | [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia]. ( Császár, A; Kovács, I; Tarján, J, 2001) |
| "Ciprofibrate treatment (100 mg/day for 1 month) effected marked reductions in both total plasma LDL and apo B-100 levels (approximately 19% and approximately 23%, respectively)." | 1.29 | Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. ( Bruckert, E; Chapman, MJ; Dejager, S, 1993) |
| " An individualized dosage of bezafibrate and repeated checks of the serum concentrations of the drug are recommended during long-term treatment of uremic patients." | 1.26 | Treatment of uremic hypertriglyceridaemia with bezafibrate. ( Anderson, P; Norbeck, HE, 1982) |
| " Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7." | 1.26 | Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ( Anderson, P; Norbeck, HE, 1981) |
| "Bezafibrate was well tolerated, hypoglycaemia or hypoglycaemic reactions were not observed." | 1.26 | [Improvement in diabetes control by treatment with bezafibrate]. ( Rüth, E; Vollmar, J, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (19.82) | 18.7374 |
| 1990's | 27 (24.32) | 18.2507 |
| 2000's | 60 (54.05) | 29.6817 |
| 2010's | 1 (0.90) | 24.3611 |
| 2020's | 1 (0.90) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, Y | 1 |
| Liu, J | 1 |
| Shi, Y | 1 |
| Wang, B | 1 |
| Wang, X | 1 |
| Wang, W | 1 |
| Sun, M | 1 |
| Xu, X | 1 |
| Jiang, H | 1 |
| Guo, M | 1 |
| He, Y | 1 |
| Ren, C | 1 |
| Cheng, L | 1 |
| Staels, B | 4 |
| Maes, M | 1 |
| Zambon, A | 1 |
| Kolovou, GD | 1 |
| Kostakou, PM | 1 |
| Anagnostopoulou, KK | 1 |
| Cokkinos, DV | 1 |
| Dominiczak, M | 1 |
| Jacobson, TA | 1 |
| Abourbih, S | 1 |
| Filion, KB | 1 |
| Joseph, L | 1 |
| Schiffrin, EL | 1 |
| Rinfret, S | 1 |
| Poirier, P | 1 |
| Pilote, L | 1 |
| Genest, J | 1 |
| Eisenberg, MJ | 1 |
| Ristic-Medic, D | 1 |
| Suzic, S | 1 |
| Vucic, V | 1 |
| Takic, M | 1 |
| Tepsic, J | 1 |
| Glibetic, M | 1 |
| Kole, LA | 1 |
| Lever, M | 1 |
| George, PM | 1 |
| Slow, S | 1 |
| Elmslie, JL | 1 |
| Shand, BI | 1 |
| Scott, RS | 1 |
| Chambers, ST | 1 |
| Ganotakis, E | 2 |
| Tsimihodimos, V | 2 |
| Bairaktari, E | 2 |
| Rizos, E | 2 |
| Athyros, V | 1 |
| Seferiades, C | 1 |
| Elisaf, M | 3 |
| Stone, NJ | 1 |
| Mikhailidis, DP | 4 |
| Kastelein, J | 1 |
| Devroey, D | 1 |
| Velkeniers, B | 1 |
| Duquet, W | 1 |
| Betz, W | 1 |
| HELLMAN, L | 1 |
| ZUMOFF, B | 1 |
| KESSLER, G | 1 |
| KARA, E | 1 |
| RUBIN, IL | 1 |
| ROSENFELD, RS | 1 |
| Geiss, HC | 1 |
| Dietlein, M | 1 |
| Parhofer, KG | 1 |
| Okopień, B | 2 |
| Krysiak, R | 1 |
| Kowalski, J | 1 |
| Madej, A | 2 |
| Belowski, D | 2 |
| Zieliński, M | 2 |
| Labuzek, K | 1 |
| Herman, ZS | 2 |
| Visnegarwala, F | 1 |
| Maldonado, M | 1 |
| Sajja, P | 1 |
| Minihan, JL | 1 |
| Rodriguez-Barradas, MC | 1 |
| Ong, O | 1 |
| Lahart, CJ | 1 |
| Hasan, MQ | 1 |
| Balasubramanyam, A | 1 |
| White, AC | 1 |
| Martínez, E | 1 |
| Tuset, M | 1 |
| Milinkovic, A | 1 |
| Miró, JM | 1 |
| Gatell, JM | 1 |
| Sebestjen, M | 1 |
| Keber, I | 1 |
| Zegura, B | 1 |
| Simcic, S | 1 |
| Bozic, M | 1 |
| Fressart, MM | 1 |
| Stegnar, M | 1 |
| Benz, R | 1 |
| Suter, PM | 1 |
| Huzarska, M | 1 |
| Kulach, A | 1 |
| Stachura-Kulach, A | 1 |
| Backes, JM | 1 |
| Gibson, CA | 1 |
| Ansell, BJ | 1 |
| Asano, M | 1 |
| Yamada, N | 1 |
| Vergès, B | 1 |
| Dufouil, C | 1 |
| Richard, F | 1 |
| Fiévet, N | 1 |
| Dartigues, JF | 2 |
| Ritchie, K | 2 |
| Tzourio, C | 1 |
| Amouyel, P | 1 |
| Alpérovitch, A | 1 |
| Fruchart, JC | 1 |
| Davidson, MH | 1 |
| Zeman, M | 2 |
| Zák, A | 1 |
| Vecka, M | 1 |
| Tvrzická, E | 1 |
| Písaríková, A | 1 |
| Stanková, B | 1 |
| Laakso, M | 1 |
| Fontaine, C | 1 |
| Guiard-Schmid, JB | 1 |
| Slama, L | 1 |
| Essid, A | 1 |
| Lukiana, T | 1 |
| Rondeau, E | 1 |
| Pialoux, G | 1 |
| Sax, PE | 1 |
| Milionis, HJ | 1 |
| Elisaf, MS | 1 |
| Balbisi, EA | 1 |
| Shiri-Sverdlov, R | 1 |
| Wouters, K | 1 |
| van Gorp, PJ | 1 |
| Gijbels, MJ | 1 |
| Noel, B | 1 |
| Buffat, L | 1 |
| Maeda, N | 1 |
| van Bilsen, M | 1 |
| Hofker, MH | 1 |
| Espinosa, RA | 1 |
| Rodríguez-Roa, E | 1 |
| Nagy, E | 1 |
| Mijares, ME | 1 |
| Rodríguez-Larralde, A | 1 |
| Gil, A | 1 |
| Lundberg, U | 1 |
| Carvajal, Z | 1 |
| Castillo, L | 1 |
| Arocha-Piñango, CL | 1 |
| Pahan, K | 1 |
| Wakatsuki, A | 1 |
| Gouni-Berthold, I | 1 |
| Krone, W | 1 |
| Schlienger, RG | 1 |
| Fedson, DS | 1 |
| Jick, SS | 2 |
| Jick, H | 1 |
| Meier, CR | 2 |
| Broncel, M | 1 |
| Balcerak, M | 1 |
| Chojnowska-Jezierska, J | 1 |
| Sposito, AC | 2 |
| Caramelli, B | 1 |
| Fonseca, FA | 1 |
| Bertolami, MC | 1 |
| Afiune Neto, A | 1 |
| Souza, AD | 1 |
| Lottenberg, AM | 1 |
| Chacra, AP | 1 |
| Faludi, AA | 1 |
| Loures-Vale, AA | 2 |
| Carvalho, AC | 1 |
| Duncan, B | 1 |
| Gelonese, B | 1 |
| Polanczyk, C | 1 |
| Rodrigues Sobrinho, CR | 1 |
| Scherr, C | 1 |
| Karla, C | 1 |
| Armaganijan, D | 1 |
| Moriguchi, E | 1 |
| Saraiva, F | 1 |
| Pichetti, G | 1 |
| Xavier, HT | 1 |
| Chaves, H | 1 |
| Borges, JL | 1 |
| Diament, J | 1 |
| Guimarães, JI | 1 |
| Nicolau, JC | 1 |
| dos Santos, JE | 2 |
| de Lima, JJ | 1 |
| Vieira, JL | 1 |
| Novazzi, JP | 2 |
| Faria Neto, JR | 1 |
| Torres, KP | 1 |
| Pinto, Lde A | 1 |
| Bricarello, L | 1 |
| Bodanese, LC | 1 |
| Introcaso, L | 1 |
| Malachias, MV | 1 |
| Izar, MC | 1 |
| Magalhães, ME | 1 |
| Schmidt, MI | 1 |
| Scartezini, M | 1 |
| Nobre, M | 1 |
| Foppa, M | 1 |
| Forti, NA | 1 |
| Berwanger, O | 1 |
| Gebara, OC | 1 |
| Coelho, OR | 2 |
| Maranhão, RC | 2 |
| dos Santos Filho, RD | 1 |
| Costa, RP | 1 |
| Barreto, S | 1 |
| Kaiser, S | 1 |
| Ihara, S | 1 |
| Carvalho, Td | 1 |
| Martinez, TL | 2 |
| Relvas, WG | 1 |
| Salgado, W | 1 |
| McClure, DL | 1 |
| Valuck, RJ | 1 |
| Glanz, M | 1 |
| Murphy, JR | 1 |
| Hokanson, JE | 1 |
| Miyauchi, K | 1 |
| Wu, J | 1 |
| Province, MA | 1 |
| Coon, H | 1 |
| Hunt, SC | 1 |
| Eckfeldt, JH | 1 |
| Arnett, DK | 1 |
| Heiss, G | 1 |
| Lewis, CE | 1 |
| Ellison, RC | 1 |
| Rao, DC | 1 |
| Rice, T | 1 |
| Kraja, AT | 1 |
| Bouknight, P | 1 |
| Mackler, L | 1 |
| Heffington, M | 1 |
| Aronow, WS | 1 |
| Townsend, ML | 1 |
| Hollowell, SB | 1 |
| Bhalodia, J | 1 |
| Wilson, KH | 1 |
| Kaye, KS | 1 |
| Johnson, MD | 1 |
| Fukumoto, Y | 1 |
| Shimokawa, H | 1 |
| Dupuy, AM | 1 |
| Carrière, I | 1 |
| Scali, J | 1 |
| Cristol, JP | 1 |
| Gambert, P | 1 |
| Ancelin, ML | 1 |
| Knopp, RH | 1 |
| Paramsothy, P | 1 |
| Atkinson, B | 1 |
| Dowdy, A | 1 |
| Brown, BG | 1 |
| Zhao, XQ | 1 |
| Becker, C | 1 |
| Kunesová, M | 1 |
| Honková, M | 1 |
| Mares, P | 1 |
| Skorepa, J | 1 |
| Rüth, E | 1 |
| Vollmar, J | 2 |
| Janka, HU | 1 |
| Standl, A | 1 |
| Holler, HD | 2 |
| Mehnert, H | 1 |
| Lang, PD | 1 |
| Palmieri, B | 1 |
| Gasparini Casari, M | 1 |
| DiBlasio, P | 1 |
| Zirilli, E | 1 |
| Grützmacher, P | 1 |
| Scheuermann, E | 1 |
| Lang, W | 1 |
| Wechsler, JG | 1 |
| Hutt, V | 1 |
| Klör, HU | 1 |
| Bode, G | 1 |
| Ditschuneit, H | 1 |
| Stratmann, FW | 2 |
| Norbeck, HE | 2 |
| Anderson, P | 2 |
| Hofmann, H | 1 |
| de la Fuente, R | 1 |
| Santos, M | 1 |
| Füsgen, I | 1 |
| Summa, JD | 1 |
| Silva, JM | 2 |
| Branco, MC | 2 |
| Pereira, M | 2 |
| Figueiredo, H | 1 |
| Jesus, LC | 2 |
| de Moura, JP | 2 |
| Ferreira, MR | 2 |
| Serra e Silva, P | 2 |
| Ferraz, A | 1 |
| Krüger, B | 1 |
| Giraud, O | 1 |
| Chanu, B | 1 |
| Farge, D | 1 |
| Parrot, F | 1 |
| Brestescher, C | 1 |
| Rouffy, J | 1 |
| Lozada, A | 1 |
| Dujovne, CA | 1 |
| Chandler, HA | 1 |
| Batchelor, AJ | 1 |
| Capps, NE | 1 |
| Wolf, HR | 1 |
| Bruckert, E | 2 |
| Dejager, S | 1 |
| Chapman, MJ | 2 |
| Betteridge, DJ | 1 |
| McLeod, AJ | 1 |
| Warren, RJ | 1 |
| Armitage, M | 1 |
| Kukharchuk, VV | 1 |
| Rozhkova, TA | 1 |
| Kotova, LA | 1 |
| Tvorogova, MG | 1 |
| Semenova, OA | 1 |
| Knipscheer, HC | 2 |
| de Valois, JC | 1 |
| van den Ende, B | 1 |
| Wouter ten Cate, J | 1 |
| Kastelein, JJ | 2 |
| Cignarella, A | 1 |
| Nastasi, M | 1 |
| Cavalli, E | 1 |
| Puglisi, L | 1 |
| de Maat, MP | 1 |
| Kluft, C | 1 |
| Ramachandran, S | 1 |
| Giles, PD | 1 |
| Hartland, A | 1 |
| Rabelo, LM | 1 |
| Anber, V | 1 |
| Millar, JS | 1 |
| McConnell, M | 1 |
| Shepherd, J | 1 |
| Packard, CJ | 1 |
| Gironet, N | 1 |
| Jan, V | 1 |
| Machet, MC | 1 |
| Machet, L | 1 |
| Lorette, G | 1 |
| Vaillant, L | 1 |
| Ganotakis, ES | 2 |
| Spyropoulos, KA | 1 |
| Jagroop, IA | 2 |
| Byrne, DJ | 1 |
| Winder, AF | 2 |
| Papadakis, JA | 1 |
| Jastrzebska, M | 1 |
| Torbus-Lisiecka, B | 1 |
| Pieczul-Mróz, J | 1 |
| Chelstowski, K | 1 |
| Kopciewicz, J | 1 |
| Naruszewicz, M | 1 |
| Beghin, L | 1 |
| Capps, N | 1 |
| Duhal, N | 1 |
| Davies, J | 1 |
| Luc, G | 1 |
| Broeders, N | 1 |
| Knoop, C | 1 |
| Abramowicz, D | 1 |
| Watts, GF | 1 |
| Dimmitt, SB | 1 |
| Dobiásová, M | 1 |
| Frohlich, J | 1 |
| Farnier, M | 1 |
| Picard, S | 1 |
| Mansur, AP | 1 |
| Rodrigues-Sobrinho, CR | 1 |
| Ramires, JA | 1 |
| Liberopoulos, E | 1 |
| Miltiadous, G | 1 |
| Harats, D | 1 |
| Yodfat, O | 1 |
| Doolman, R | 1 |
| Gavendo, S | 1 |
| Marko, D | 1 |
| Shaish, A | 1 |
| Sela, BA | 1 |
| Kovács, I | 1 |
| Tarján, J | 1 |
| Császár, A | 1 |
| Aguilar-Salinas, CA | 1 |
| Fanghänel-Salmón, G | 1 |
| Meza, E | 1 |
| Montes, J | 1 |
| Gulías-Herrero, A | 1 |
| Sánchez, L | 1 |
| Monterrubio-Flores, EA | 1 |
| González-Valdez, H | 1 |
| Gómez Pérez, FJ | 1 |
| Lipscombe, J | 1 |
| Bargman, JM | 1 |
| Gajdos, M | 1 |
| Mongiellová, V | 1 |
| Huttová, D | 1 |
| Cibulová, L | 1 |
| Krivosíková, Z | 1 |
| Spustová, V | 1 |
| Dzúrik, R | 1 |
| Fischer, M | 1 |
| Falkensammer, C | 1 |
| Priego, JG | 1 |
| Maroto, ML | 1 |
| Piña, M | 1 |
| Catalán, RE | 1 |
| Pfeiffer, M | 1 |
| Tilsner, V | 1 |
| Takeuchi, I | 1 |
| Petit, D | 1 |
| Bonnefis, MT | 1 |
| Rey, C | 1 |
| Infante, R | 1 |
| Lam, HC | 1 |
| Li, SH | 1 |
| Wang, JT | 1 |
| Tang, KT | 1 |
| Ho, LT | 1 |
| Kasiske, BL | 2 |
| O'Donnell, MP | 2 |
| Garvis, WJ | 1 |
| Keane, WF | 2 |
| Stähelin, HB | 1 |
| Hartmann, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of the Safety, Efficacy, and Tolerability of Ezetimibe (Zetia) in Combination With Statin Therapy for the Treatment of Elevated LDL Cholesterol in HIV-Infected Subjects[NCT00099684] | 44 participants (Actual) | Interventional | 2005-11-30 | Completed | |||
| A Pilot Study to Determine the Impact on Dyslipidemia of the Addition of Tenofovir to Stable Background Antiretroviral Therapy in HIV-Infected Subjects[NCT00109603] | 17 participants (Actual) | Interventional | 2005-05-31 | Completed | |||
| Myocardial Adipose Inflammation and Pericardial Adipose Volume as Markers for Coronary Artery Disease In HIV Positive Patients[NCT02399384] | 12 participants (Anticipated) | Observational | 2015-01-14 | Completed | |||
| A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction[NCT00203476] | Phase 4 | 30 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers[NCT01148004] | Phase 1 | 25 participants (Actual) | Interventional | 2010-05-13 | Completed | ||
| Effect of a Nutritional Support System to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III[NCT04507867] | 80 participants (Actual) | Interventional | 2020-09-07 | Completed | |||
| Effect of Nutritional Intervention and Olive Oil in Severe Obesity: Randomized Controlled Trial[NCT02463435] | 229 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00203476)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Niacin | 0 |
| Colestipol | 0 |
| Ezetimibe | 0 |
Each participant had his LDL goal calculated based on the NCEP ATPIII guidelines. (NCT00203476)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Niacin | 6 |
| Colestipol | 6 |
| Ezetimibe | 9 |
(NCT00203476)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Niacin | 1 |
| Colestipol | 1 |
| Ezetimibe | 2 |
(NCT00203476)
Timeframe: baseline and 12 weeks
| Intervention | mg/dl (Mean) | |
|---|---|---|
| baseline | 12 weeks | |
| Colestipol | 39.22 | 37.56 |
| Ezetimibe | 32.90 | 34.70 |
| Niacin | 42.33 | 43.00 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
Total number of patients with gastrointestinal symptoms at the end of follow-up at day 40.Those symptoms perceived abdominal region (pain, burn, pressure, nausea, vomiting) (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 4 |
| Intervention Group | 3 |
The ratio between the water assimilated into the body and that lost from the body, in milliliters. (NCT04507867)
Timeframe: It is evaluated on day 3 of hospital stay (duration approximately 10 minutes).
| Intervention | milliliters (Mean) |
|---|---|
| Control Group | 123.4 |
| Intervention Group | 456.6 |
Patients who were intubated during their hospital stay and died before completing follow-up on day 40. (NCT04507867)
Timeframe: 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 5 |
| Intervention Group | 1 |
The need to continue with supplemental oxygen at hospital discharge. Categories: 1. Yes, 2. No. (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 23 |
| Intervention Group | 26 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Leukocytes <10x10^3/μL | 3 |
| Leukocytes >10x10^3/μL | 5 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Neutrophils <80% | 0 |
| Neutrophils >80% | 8 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| RCP <150 mg/L | 1 |
| RCP >150 mg/L | 7 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Urea <40 mg/dL | 4 |
| Urea >40 mg/dL | 4 |
Association between the presentation of certain laboratory parameters taken at baseline with the overall mortality of discharged patients compared to deceased patients. (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Fibrinogen <700 mg/dL | 2 |
| Fibrinogen >700 mg/dL | 6 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Procalcitonin <0.5 ng/mL | 4 |
| Procalcitonin >0.5 ng/mL | 4 |
Association between the presentation of certain laboratory parameters taken in the baseline period, with te overall mortality of discharge patients in comparison with deceased patients (NCT04507867)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Ureic Nitrogen <22 mg/dL | 4 |
| Ureic Nitrogen >22 mg/dL | 4 |
Refers to the subjective sensation of increased abdominal pressure without an increase in abdominal size, the number of defecations were quantified at day 3 and compared between both groups. (NCT04507867)
Timeframe: Day 3
| Intervention | defecations (Mean) |
|---|---|
| Control Group | 0.81 |
| Intervention Group | 1.41 |
Is a visible increase in abdominal girth.1. Present, 2. Absent. (NCT04507867)
Timeframe: Day 3
| Intervention | percent of participants (Number) |
|---|---|
| Control Group | 51.6 |
| Intervention Group | 19.4 |
Total number of patients who died before day 40 of follow-up. (NCT04507867)
Timeframe: 40 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 7 |
| Intervention Group | 1 |
Overall survival, the total number of patients included in the study and completed a 40-day follow-up. (NCT04507867)
Timeframe: 40 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 33 |
| Intervention Group | 39 |
the total number of patients with oxygen saturation >90% on day 3 of their hospital stay. (NCT04507867)
Timeframe: day 3.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 34 |
| Intervention Group | 37 |
"The Bristol Stool Form Scale categorizes stools into one of seven stool types ranging from type 1 (hard lumps) to type 7 (watery diarrhea). Type 3 and 4 were considered Normal." (NCT04507867)
Timeframe: day 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 8 |
| Intervention Group | 13 |
Persistence of clinical signs and symptoms that arise after developing COVID-19, and are not explained by an alternative diagnosis. 1. Present. 2. Absent. (NCT04507867)
Timeframe: Day 40.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 9 |
| Intervention Group | 8 |
total number of patients included in the study who progressed to mechanical ventilation during the first 10 days of hospital stay. (NCT04507867)
Timeframe: 10 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 7 |
| Intervention Group | 3 |
The oxygen saturation without supplementary oxygen is taken at the control appointment 40 days after hospital discharge. (NCT04507867)
Timeframe: day 40
| Intervention | percentage (Mean) |
|---|---|
| Control Group | 90.39 |
| Intervention Group | 92.08 |
Total number of patients who were intubated, extubated, discharged and completes the 40 day follow-up (NCT04507867)
Timeframe: 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 2 |
| Intervention Group | 2 |
It is recorded for how many days the treating doctor asked the patients to continue to administer supplemental oxygen after hospital discharge (NCT04507867)
Timeframe: day 40
| Intervention | days (Mean) |
|---|---|
| Control Group | 57.6 |
| Intervention Group | 43.8 |
Is defined as at least a 5% reduction in weight from the baseline level.Total number of patients with weight loss at the end of follow-up at day 40 (NCT04507867)
Timeframe: Day 40
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Group | 8 |
| Intervention Group | 8 |
Difference in oxygen delivery between the baseline period and day 3 of hospital stay in each group. (NCT04507867)
Timeframe: baseline and day 3
| Intervention | Liters (L) (Mean) | |
|---|---|---|
| Baseline | Day 3 | |
| Control Group | 5.9 | 6 |
| Intervention Group | 6 | 4.5 |
Is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders, includes 9 items, which evaluate the presence of depressive symptoms based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders version 4, during the last 2 weeks, how often the patient presented depressive symptoms. According to the sum of the score obtained, the following 4 categories will be considered: 0-4 minimum existence or absence of depressive symptoms; 5-9 = mild depressive symptoms; 10-14 = moderate depressive symptoms; 15-19 = moderate to severe depressive symptoms; 20-27 = severe depressive symptoms. (NCT04507867)
Timeframe: baseline and hospital discharge
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Hospital discharge | |
| Control Group | 3.66 | 1.50 |
| Intervention Group | 5.3 | 1.9 |
Quick-Sequential Organ Failure Assessment (qSOFA) score gives 0 to 3 points. ≥2 in the setting of suspected infection had a high predicted in-hospital mortality rate and could be considered septic. (NCT04507867)
Timeframe: Baseline and Day 3
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Day 3 | |
| Control Group | 0.42 | 0.51 |
| Intervention Group | 0.65 | 0.43 |
34 reviews available for clofibric acid and Hyperlipemia
| Article | Year |
|---|---|
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; D | 2008 |
Therapeutic effects of fibrates in postprandial lipemia.
Topics: Animals; Clinical Trials as Topic; Clofibric Acid; Humans; Hyperlipidemias; Hypolipidemic Agents; Po | 2008 |
Myopathy with statin-fibrate combination therapy: clinical considerations.
Topics: Clofibric Acid; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias | 2009 |
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Fe | 2009 |
Fibrates plus betaine: a winning combination?
Topics: Betaine; Clofibric Acid; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolipidemic Agents; L | 2010 |
Current drug treatments for lipid management.
Topics: Bile Acids and Salts; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; | 2002 |
What future for combination therapies?
Topics: Bile Acids and Salts; Clofibric Acid; Drug Therapy, Combination; Fish Oils; Forecasting; Humans; Hyp | 2003 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Clofibric Acid; HIV Infections; HIV Protease Inhibitors; Huma | 2004 |
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric A | 2004 |
Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
Topics: Cholesterol, LDL; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipid | 2005 |
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug | 2005 |
[Dyslipidemia management in patients with impaired glucose tolerance].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Clofibric Acid; Eicosapen | 2005 |
Diabetic dyslipidaemia: insights for optimizing patient management.
Topics: Arteriosclerosis; Cardiovascular Agents; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopa | 2005 |
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Inflamm | 2005 |
Management of dyslipidemia in patients with complicated metabolic syndrome.
Topics: Clofibric Acid; Fatty Liver; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-Co | 2005 |
Lipids in type 2 diabetes.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; H | 2002 |
Strategies for management and treatment of dyslipidemia in HIV/AIDS.
Topics: Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Clofibric Acid; Drug Interactions; H | 2006 |
Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylg | 2000 |
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Th | 2006 |
Lipid-lowering drugs.
Topics: Alzheimer Disease; Clofibric Acid; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2006 |
[Hyperlipidemia].
Topics: Clinical Trials as Topic; Clofibric Acid; Estrogen Replacement Therapy; Estrogens; Female; Humans; H | 2006 |
[Favorable effects of decreasing lipids in patients with diabetes mellitus].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2006 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric | 2007 |
[Role of fibrate in cardiovascular disease prevention].
Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hyperlipidemias | 2007 |
FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia.
Topics: Anion Exchange Resins; Azetidines; Clofibric Acid; Evidence-Based Medicine; Ezetimibe; Fatty Acids, | 2007 |
Management of hyperlipidemia with statins in the older patient.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA | 2006 |
[Adverse effects of lipid-lowering medications].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clofibric Acid; Contraindications; Humans; Hydroxymethyl | 2007 |
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol | 2008 |
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2008 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Dru | 1994 |
Ciprofibrate--a profile.
Topics: Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents | 1993 |
The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Topics: Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents | 1996 |
Fibrates, dyslipoproteinaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clin | 1999 |
Diabetes: statins, fibrates, or both?
Topics: Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Huma | 2001 |
27 trials available for clofibric acid and Hyperlipemia
| Article | Year |
|---|---|
Serum and erythrocyte membrane phospholipids fatty acid composition in hyperlipidemia: effects of dietary intervention and combined diet and fibrate therapy.
Topics: Aged; American Heart Association; Clofibric Acid; Erythrocyte Membrane; Fatty Acids; Female; Humans; | 2009 |
Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
Topics: Analysis of Variance; Cholesterol; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hyperli | 2002 |
Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.
Topics: Adult; Aged; Body Mass Index; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diabetes Complications; | 2003 |
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.
Topics: Adult; Aged; Arteriosclerosis; Clofibric Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2004 |
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Prote | 2004 |
N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
Topics: Adult; Albuminuria; Cholesterol Esters; Clofibric Acid; Diabetes Mellitus, Type 1; Dietary Supplemen | 2006 |
[Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
Topics: Adolescent; Adult; Aged; Cholesterol; Clofibric Acid; Coronary Artery Disease; Female; Fibric Acids; | 2006 |
[Therapeutic effects of bezafibrate in hyperlipidemia].
Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; Humans; Hype | 1983 |
[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Topics: Aged; Bezafibrate; Carbohydrate Metabolism; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Di | 1982 |
Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
Topics: Adenosine Diphosphate; Adult; Aged; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Aci | 1981 |
Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyper | 1981 |
[An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
Topics: Adolescent; Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Doubl | 1980 |
[Effectiveness of ciprofibrate. Open study in a Portuguese population].
Topics: Adolescent; Adult; Aged; Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemi | 1995 |
[Safety of ciprofibrate. Open study in a Portuguese population].
Topics: Adolescent; Adult; Aged; Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemi | 1995 |
Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
Topics: Cholesterol; Cholesterol, HDL; Clofibric Acid; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolip | 1994 |
[A trial of the use of the hypolipidemic preparation Lipanor (ciprofibrate) in patients with primary hyperlipidemia].
Topics: Adolescent; Adult; Clofibric Acid; Female; Fibric Acids; Hemodynamics; Humans; Hyperlipidemias; Hypo | 1996 |
Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
Topics: Adult; Aged; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Follow-Up Studie | 1996 |
Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
Topics: Adult; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Gemfibrozil; Humans; Hyperlipidemias; Hypol | 1997 |
[Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholesterol; Clofibric Acid; Female; Humans; Hyperlipide | 1996 |
Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Diabetes Mellitus, Type 1; Factor VII; Fibrinogen; Humans; Hyperli | 1999 |
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
Topics: Analysis of Variance; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibric Acid; Double- | 2001 |
Homocysteine elevation with fibrates: is it a class effect?
Topics: Adult; Bezafibrate; Clofibric Acid; Dietary Fats; Female; Fibric Acids; Homocysteine; Humans; Hyperl | 2001 |
Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, | 2001 |
Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
Topics: Aged; Arteriosclerosis; Aspirin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Fi | 2001 |
[New drug combination for medical management of hyperlipemia: clinical study].
Topics: Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; | 1977 |
The antilipemic effectiveness of aluminium clofibrate on hyperlipidemic patients with or without diabetes mellitus.
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Diabetes Complications; Double-Bl | 1987 |
[Long-term effect of alufibrate in various types of hyperlipidaemia (author's transl)].
Topics: Adult; Aged; Aluminum; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Drug Evalu | 1974 |
50 other studies available for clofibric acid and Hyperlipemia
| Article | Year |
|---|---|
The combination of sesamol and clofibric acid moieties leads to a novel potent hypolipidemic agent with antioxidant, anti-inflammatory and hepatoprotective activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Benzodioxoles; Clofibric Acid; Dose- | 2021 |
Hyperlipidaemia and cardiovascular disease: nonlipid-lowering effects of omega-3 fatty acids, statins and fibrates.
Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Fatty Acids, Omega-3; Femal | 2009 |
Lipid disorders.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary D | 2009 |
Effects of various fibrates on serum alkaline phosphatase activity.
Topics: Alkaline Phosphatase; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; H | 2002 |
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholestero | 2003 |
REDUCTION OF CHOLESTEROL AND LIPIDS IN MAN BY ETHYL P-CHLOROPHENOXYISOBUTYRATE.
Topics: Butyrates; Cholesterol; Clofibric Acid; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Male | 1963 |
Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Clofibric Acid; Cohort Studies; Female; H | 2004 |
Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
Topics: Atorvastatin; Cells, Cultured; Clofibric Acid; Cytokines; Fenofibrate; Fibrinolytic Agents; Heptanoi | 2005 |
APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study.
Topics: Aged; Aged, 80 and over; Apolipoprotein E4; Apolipoproteins E; Causality; Cholesterol; Clofibric Aci | 2005 |
Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
Topics: Anti-HIV Agents; Clofibric Acid; Dideoxynucleosides; Drug Hypersensitivity; Drug Interactions; Drug | 2005 |
Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Topics: Animals; Apolipoprotein E2; Apolipoproteins E; ATP-Binding Cassette Transporters; Clofibric Acid; Di | 2006 |
Statins and the risk of pneumonia: a population-based, nested case-control study.
Topics: Adult; Aged; Anticholesteremic Agents; Case-Control Studies; Clofibric Acid; Databases as Topic; Fam | 2007 |
[IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology].
Topics: Adult; Age Distribution; Aged; Cholesterol; Clofibric Acid; Coronary Artery Disease; Diet; Female; H | 2007 |
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population.
Topics: Age Factors; Aged; Clofibric Acid; Cohort Studies; Confidence Intervals; Confounding Factors, Epidem | 2007 |
An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study.
Topics: Adult; Aged; Black or African American; Clofibric Acid; Female; Genetic Linkage; Genetic Markers; Ge | 2007 |
A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Cohort Studies; Female; Fish Oils; HIV Infections; Humans; | 2007 |
Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Drug Therapy, Combina | 2008 |
Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.
Topics: Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Clofibric Acid; Comorbidity; Databas | 2008 |
[Improvement in diabetes control by treatment with bezafibrate].
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitu | 1982 |
[Bezafibrate and delayed action etofibrate in hyperlipidemia].
Topics: Bezafibrate; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Aci | 1983 |
[Bezafibrate in primary hyperlipidemias (author's transl)].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Hu | 1982 |
[What are the possibilities in the treatment of primary hyperlipidemia in diabetes mellitus?].
Topics: Bezafibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents | 1982 |
Treatment of uremic hypertriglyceridaemia with bezafibrate.
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Kidney Failur | 1982 |
[Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Body Weight; Carbohydrate Metabolism; Clofibrate; Clofibric A | 1981 |
[Toxicological and pharmacological studies on a new drug: pirfibrate (EL-466) (author's transl)].
Topics: Abnormalities, Drug-Induced; Animals; Clofibrate; Clofibric Acid; Diet, Atherogenic; Dogs; Female; F | 1980 |
Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Hyperlipidemias; H | 1981 |
Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; | 1994 |
[Acute rhabdomyolysis associated with digestive disorders during a voluntary overdose of ciprofibrate].
Topics: Abdominal Pain; Acute Disease; Adult; Clofibric Acid; Diarrhea; Drug Overdose; Fibric Acids; Humans; | 1995 |
Ciprofibrate and lipid profile.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemi | 1994 |
Lipid profiles on fibric-acid derivatives.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Female; Fibric Acids; Humans; Hyperlipidemias; Hypoli | 1994 |
Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
Topics: Adult; Apolipoprotein B-100; Apolipoproteins B; Clofibric Acid; Fibric Acids; Humans; Hypercholester | 1993 |
Abnormal lipid profiles on fibrate derivatives.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic | 1996 |
Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate.
Topics: Animals; Anthocyanins; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Experimental; Fatty Acids, | 1996 |
Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment.
Topics: Acute Kidney Injury; Adult; Anti-Inflammatory Agents, Non-Steroidal; Clofibric Acid; Drug Interactio | 1997 |
Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
Topics: Adult; Aged; Aorta; Apolipoproteins B; Arginine; Chondroitin Sulfates; Clofibric Acid; Coronary Arte | 1997 |
[Chronic radiodermatitis after heart catheterization: the contributing role of ciprofibrate (Lipanor)?].
Topics: Cardiac Catheterization; Chronic Disease; Clofibric Acid; Female; Fibric Acids; Glucocorticoids; Hum | 1998 |
Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
Topics: Body Weight; Cardiovascular Diseases; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hype | 1998 |
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Clof | 1999 |
Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Lipo | 1999 |
Drug treatment of lipid disorders.
Topics: Clofibric Acid; Creatinine; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Urea | 1999 |
[The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Topics: Adult; Aged; Arteriosclerosis; Child; Cholesterol; Cholesterol, HDL; Clofibric Acid; Esterification; | 2000 |
Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hyperthyr | 2001 |
[Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
Topics: Adult; Blood Flow Velocity; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Endothelium, Vascula | 2001 |
Fibrate-induced increase in blood urea and creatinine.
Topics: Bezafibrate; Blood Urea Nitrogen; Clofibric Acid; Creatinine; Fenofibrate; Fibric Acids; Humans; Hyp | 2001 |
Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in hyperlipidemic rats.
Topics: Animals; Clofibrate; Clofibric Acid; Diet; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; | 1979 |
[Influence of etofibrate on plasmaviscosity in hyperlipoproteinemias (author's transl)].
Topics: Blood Viscosity; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Male; Mid | 1978 |
[Diabetes mellitus and secondary hyperlipidemia].
Topics: Adipose Tissue; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibric Acid; Diabetes Comp | 1992 |
Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats.
Topics: Animals; Apolipoproteins; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hyperl | 1988 |
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Disease Models, Animal; Glomerulonephritis; Glomer | 1988 |
The role of lipids in progressive glomerular disease.
Topics: Animals; Clofibric Acid; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Humans; Hyperlipid | 1987 |